「PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma」の関連論文
-
MYC Upregulation Is a Useful Biomarker for Preoperative Neoadjuvant Chemotherapy Combined With Anti-EGFR in Liver Metastasis from Colorectal Cancer
-
Kinetic information from dynamic contrast-enhanced MRI enables prediction of residual cancer burden and prognosis in triple-negative breast cancer,a retrospective study
-
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer
-
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer
-
Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
-
Increased expression of programmed cell death ligand 1 and galectin 9 in transplant recipients who achieved tolerance after immunosuppression withdrawal
-
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
-
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma
-
Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
-
Finding potential synergistic drugs to reduce chemo-resistance for the treatment of highly malignant tumors in female
-
転移性尿路上皮癌に対するGC療法における, Gemcitabine投与後の発熱の臨床的意義の検討: 多施設共同後ろ向き研究
-
外科的に切除された膵癌におけるST2発現の臨床病理学的及び予後との関連性の検討
-
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer
-
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
-
Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial
-
Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation
-
Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
-
Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease
-
Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
-
Clinical and Basic Research for Ovarian Cancer
-
MDM4 as a prognostic factor for patients with gastric cancer with low expression of p53:immunohistochemical study of p53, MDM2, and MDM4
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Modified Glasgow prognostic score is a pre-surgical prognostic marker of disease mortality in upper urinary tract urothelial carcinoma
-
Studies on the Enhancement of Antitumor Effect by Drug Combination in Molecular-Targeted Therapy of Cancer
-
Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients (本文)
-
Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma
-
Significance of Wnt/β-Catenin Signal Activation for Resistance to Neoadjuvant Chemoradiotherapy in Rectal Cancer
-
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
-
Neutrophil–lymphocyte Ratio and Histological Response Correlate With Prognosis of Gastric Cancer Undergoing Neoadjuvant Chemotherapy
-
Comparison of efficacy and safety outcomes of anticancer drugs between Japanese patients and the overall population in multi-regional clinical trials
-
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
-
HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function
-
Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing (本文)
-
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
-
Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1
-
Intensity-modulated radiation therapy for lymph node oligo-recurrence
-
The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry
-
Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies
-
The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer
-
Occurrence of cholangiocarcinoma, three years after negative seroconversion of anti-TIF1γ antibody, in a dermatomyositis patient
-
Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder
-
Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors
-
A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice
-
A never-ending FLT3 story
-
Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine
-
Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma Considering Alternative Treatment Approaches
-
Autoantibodies against the plakin family proteins as a novel marker for chronic graft-versus-host disease of the lung
-
Evaluating the effect of lenvatinib on sorafenib-resistant hepatocellular carcinoma cells
-
TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer